Christina Dold, PhD

Senior Director, ID Program Lead
Moderna, Inc

Disclosure(s): Moderna: Stocks/Bonds (Public Company)

Poster(s):

• (P-1485) Safety and Immunogenicity of mRNA-1982 and mRNA-1975, mRNA Vaccine Candidates for Prevention of Lyme Disease in Healthy Adults: Interim Results of a Phase 1/2, Randomized, Observer-Blind, Placebo-Controlled, Dose-Ranging Trial
  Tuesday, October 21, 2025

  12:15 PM - 1:30 PM US ET